IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+17.97%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$261M
AUM Growth
+$261M
(+18%)
Cap. Flow
+$21.1M
Cap. Flow
% of AUM
8.09%
Top 10 Holdings %
Top 10 Hldgs %
55.54%
Holding
65
New
16
Increased
14
Reduced
15
Closed
5
Top Buys
| 1 |
AKAO
Achaogen, Inc.
AKAO
|
$7.07M |
| 2 |
Incyte
INCY
|
$6.51M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$6.25M |
| 4 |
Bristol-Myers Squibb
BMY
|
$5.33M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$4.92M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$10.9M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$8.18M |
| 3 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$5.58M |
| 4 |
Gilead Sciences
GILD
|
$5.03M |
| 5 |
SHPG
Shire pic
SHPG
|
$4.7M |
Sector Composition
| 1 | Healthcare | 90.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $21.7M | 8.29% | 174,022 -7,700 | -4% | -$958K |
|
2
Biogen
BIIB
$19.4B
| $20.6M | 7.89% | 75,408 +9,500 | +14% | +$2.6M |
|
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $17.5M | 6.69% | 45,130 +12,700 | +39% | +$4.92M |
|
|
4
Incyte
INCY
$16.5B
| $17M | 6.52% | 127,475 +48,700 | +62% | +$6.51M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $15.1M | 5.78% | 124,641 -9,200 | -7% | -$1.12M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $13.4M | 5.13% | 122,522 +17,000 | +16% | +$1.86M |
|
|
SHPG
7
DELISTED
Shire pic
SHPG
| $11.9M | 4.55% | 68,200 -27,000 | -28% | -$4.7M |
|
8
Amgen
AMGN
$155B
| $11M | 4.21% | 67,104 -13,000 | -16% | -$2.13M |
|
9
Illumina
ILMN
$15.8B
| $9.84M | 3.77% | 57,641 +1,700 | +3% | +$290K |
|
|
AKAO
10
DELISTED
Achaogen, Inc.
AKAO
| $7.07M | 2.7% | +280,038 | New | +$7.07M |
|
|
11
Gilead Sciences
GILD
$140B
| $6.91M | 2.65% | 101,784 -74,000 | -42% | -$5.03M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.82M | 2.61% | 77,666 +2,000 | +3% | +$176K |
|
|
13
Supernus Pharmaceuticals
SUPN
$2.53B
| $6.25M | 2.39% | +200,000 | New | +$6.25M |
|
|
14
Bristol-Myers Squibb
BMY
$96B
| $5.33M | 2.04% | +98,000 | New | +$5.33M |
|
|
ENTL
15
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $4.7M | 1.8% | 341,468 -61,852 | -15% | -$852K |
|
16
Halozyme
HALO
$8.56B
| $4.64M | 1.77% | 358,000 +300,000 | +517% | +$3.88M |
|
|
XLRN
17
DELISTED
Acceleron Pharma Inc.
XLRN
| $4.51M | 1.73% | 170,606 +152,000 | +817% | +$4.02M |
|
|
KITE
18
DELISTED
Kite Pharma, Inc.
KITE
| $4.35M | 1.66% | 55,500 +19,000 | +52% | +$1.49M |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.09M | 1.56% | +65,000 | New | +$4.09M |
|
20
Jazz Pharmaceuticals
JAZZ
$7.75B
| $3.92M | 1.5% | 27,000 +8,800 | +48% | +$1.28M |
|
|
TSRO
21
DELISTED
TESARO, Inc.
TSRO
| $3.62M | 1.38% | 23,500 -71,000 | -75% | -$10.9M |
|
|
DERM
22
DELISTED
Dermira, Inc.
DERM
| $3.58M | 1.37% | 105,000 +60,000 | +133% | +$2.05M |
|
|
ADMS
23
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $3.24M | 1.24% | 185,234 | – | – |
|
|
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $2.87M | 1.1% | 108,248 +43,248 | +67% | +$1.15M |
|
25
Exelixis
EXEL
$10.1B
| $2.84M | 1.09% | 131,000 -54,000 | -29% | -$1.17M |
|